Clinical trials: Neuropathy (Disorder)
Small Fiber Neuropathy, Diabetes Mellitus
Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy
The primary objective of this study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with confirmed small fiber neuropathy (SFN) that is idiopathic or associated with diabetes mellitus.
- Trial name
- NCT03339336
- Testing
- BIIB074
- Where
- 97 sites in Bulgaria, Canada and 12 more
- Volunteers
- 265 people
- Sponsor
- Biogen
Healthy
Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg
The purpose of this clinical trial is to (1) evaluate the bioequivalence(BE) of GLA5PR GLARS-NF3 tablet 150mg administered regular diet relative to GLA5PR GLARS-NF1 tablet 150mg administered regular diet and (2) determine the…
- Trial name
- NCT02955472
- Testing
- GLA5PR GLARS-NF3 tablet 150mg, GLA5PR GLARS-NF1 tablet 150mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GL Pharm Tech Corporation
Painful Diabetic Neuropathy
A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic Neuropathy
The purpose of this study is to determine if lacosamide (SPM 927) is safe if taken for a longer period of time and whether it continues to work well to treat pain.
- Trial name
- NCT00220337
- Testing
- Lacosamide
- Where
- Germany
- Volunteers
- 371 people
- Sponsor
- UCB Pharma
Chronic Pain
Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time
The primary objective of this study is to evaluate the safety of hydrocodone extended-release tablets when used over a 12-month period in patients with chronic pain, as assessed by adverse events, clinical laboratory results…
- Trial name
- NCT01223365
- Testing
- Hydrocodone ER
- Where
- 54 sites in United States
- Volunteers
- 330 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cardiac Amyloidosis
PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY
Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-up of proteins called amyloid.
- Trial name
- PATHWAY-RCT (NCT05098665)
- Testing
- Telemonitoring service
- Where
- United Kingdom
- Volunteers
- 320 people
- Sponsor
- Richmond Research Institute
Advanced Solid Tumors
Phase I Trial of Oral PX-866
This study is being conducted to determine the safety and maximally tolerated dose of PX-866 when given orally on two different schedules: daily on days 1-5 and 8-12 of a 28 day cycle and daily on days 1-28 of a 28 day cycle.
- Trial name
- NCT00726583
- Testing
- PX-866
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Cascadian Therapeutics Inc.
Specific Advanced Solid Tumors
Study of ACR-2316 in Specific Advanced Solid Tumors
This is a first in-human, Open-label Phase 1/2 study to assess the safety and activity of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
- Trial name
- NCT06667141
- Testing
- ACR-2316
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Acrivon Therapeutics
Postherpetic Neuralgia, Diabetic Neuropathy
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a…
- Conditions
- Postherpetic Neuralgia, Diabetic Neuropathy, Complex Regional Pain Syndrome, Carpal Tunnel Syndrome
- Trial name
- NCT00904202
- Testing
- Gabapentin + Lidoderm®
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Amyloidosis, Amyloid Cardiomyopathy
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause…
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
- Trial name
- NCT06563895
- Testing
- Acoramidis
- Where
- 104 sites in United States, Argentina and 22 more
- Volunteers
- 587 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of…
- Conditions
- Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
- Trial name
- SENSE (NCT04932031)
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sapere Bio
Sensorimotor Gait Disorder, Neurologic Ambulation Disorder
Clinical Study of the L300 Versus Ankle-foot Orthosis (AFO) on Post-Stroke Subjects With Foot Drop
The objective of this study is to determine the effectiveness of the NESS L300 (L300) in improving gait parameters, function, and quality of life among stroke subjects (greater than or equal to 3 months post stroke)with drop foot.
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis
- Trial name
- L300 (NCT01138995)
- Testing
- Ness L300, Ankle-foot orthosis
- Where
- 11 sites in United States
- Volunteers
- 197 people
- Sponsor
- Bioness Inc
Painful Diabetic Neuropathy
Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy.
SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful…
- Trial name
- NCT00546351
- Testing
- Lacosamide
- Where
- 101 sites in Austria, Belgium and 13 more
- Volunteers
- 621 people
- Sponsor
- UCB Pharma
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related…
- Trial name
- NCT04980872
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Foot Ulcer, Diabetic
NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
This study was designed to determine the heal rate of diabetic foot ulcers at 4 weeks, and complete closure at 8 and 12 weeks of patients treated with either NuShield or Affinity compared to standard care alone.
- Trial name
- NCT02461641
- Testing
- NuShield, Affinity, Standard of Care
- Where
- 7 sites in United States
- Volunteers
- 96 people
- Sponsor
- NuTech Medical, Inc
Diabetic Foot Ulcer
Affinity Prospective Diabetic Foot Trial Crossover Group
This study is an extension of the randomized controlled trial NT-DFU-AFF-01. Subjects that were randomized to the Standard of Care group will be able to crossover to the NT-DFU-AFF-02 trial and receive Affinity fHSAM if certain…
- Trial name
- NCT03205436
- Testing
- Affinity human amniotic membrane
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Organogenesis
Depressive Disorder, Major, Diabetic Neuropathies
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
To evaluate the effects of multiple oral doses of desvenlafaxine sustained release (DVS SR) and paroxetine on the biotransformation of codeine to morphine in healthy subjects.
- Conditions
- Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms
- Trial name
- NCT00456898
- Testing
- desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Diabetes
A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain
In this study, subjects with diabetic neuropathic pain (DNP) will be treated for 12 weeks with either placebo, 40 or 80 mg sustained release sodium nitrite (TV1001sr) twice daily.
- Trial name
- NCT02412852
- Testing
- Sodium nitrite
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- TheraVasc Inc.
Multiple Sclerosis
A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis
Phase 1 will test single oral doses of PRO-1562 in healthy adult subjects to characterize the safety and the amount of drug that is absorbed into the body.
- Trial name
- NCT07826689
- Testing
- PRO-1562 Oral Capsules
- Where
- Australia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Progentos Therapeutics
Diabetic Foot Ulcer
Evaluation of Safety of Low Level Laser Device Treatment in Chronic Wounds
This is a randomized, double blind, placebo-controlled study to evaluate the safety of the low level laser MC-8XL device treatment in subjects with an unsuccessfully treated Diabetic Foot Ulcer (DFU) that has been present for at…
- Trial name
- NCT03204149
- Testing
- MC-8XL low level laser device and Standard wound care
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Medical Coherence LLC
Diabetic Foot Ulcer
Clinical Trial Evaluating the Safety and Efficacy of the Use of Chitosan Gel in Patients With Chronic Wounds
Type 1 and Type 2 diabetic patients with diabetic foot ulcer will be recruited and screened for participation in the study. Eligible patients will be randomized 1:1 to either experimental or control group and undergo 10-weeks of…
- Trial name
- CHITOWOUND (NCT04178525)
- Testing
- ChitoCare gel
- Where
- 5 sites in Croatia, Slovenia
- Volunteers
- 46 people
- Sponsor
- Primex ehf